[Treatment with intravenous iron and ferritin level].
作者信息
Fernández-Gallego J, Martín M A, Sujan S, Vega E
出版信息
Nefrologia. 2010;30(3):371-2. doi: 10.3265/Nefrologia.pre2010.Mar.10258.
Abstract
摘要
相似文献
1
[Treatment with intravenous iron and ferritin level].
Nefrologia. 2010;30(3):371-2. doi: 10.3265/Nefrologia.pre2010.Mar.10258.
2
Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Nephrology (Carlton). 2010 Apr;15(3):288-93. doi: 10.1111/j.1440-1797.2009.01184.x.
3
The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
Clin Nephrol. 1995 Oct;44(4):238-40.
4
Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
J Ren Care. 2008 Sep;34(3):112-5. doi: 10.1111/j.1755-6686.2008.00026.x.
5
Changing patterns of anemia management in US hemodialysis patients.
Am J Med. 2012 Sep;125(9):906-14.e9. doi: 10.1016/j.amjmed.2012.03.011.
6
7
Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
Int J Artif Organs. 1998 Nov;21(11):681-6.
8
[Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
Nefrologia. 2006;26(1):143-4.
9
Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Nephrol Dial Transplant. 1996 Jun;11(6):1079-83.
10
Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
Nephrol Nurs J. 2001 Aug;28(4):429-34.
Zotero 插件